With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for ...

CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management’s recent comments on faster CASGEVY ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

The company had fallen out of investor favor; its recovery was impressive.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.80, moving -2.19% from the previous trading session.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

CRISPR Therapeutics ( CRSP) is set to snap six straight sessions of losses, as the stock was up more than 3% at $53.32 on Monday. The company lost 8.5% over the past six sessions. The stock closed ...

Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026--Phase 1a clinical data for CTX310® ...

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that ...

Crispr stock yo-yoed while Intellia stock surged, on promising updates for their gene-editing efforts in cholesterol treatment and a swelling disorder. At the American Heart Association conference in ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...

CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP ...